← Back to headlines
Leerink Identifies Altimmune as Attractive Play in MASH Therapeutics Market
Leerink has highlighted Altimmune (ALT) as an attractive investment opportunity within the growing MASH (Metabolic Dysfunction-Associated Steatohepatitis) therapeutics market.
5 Jul, 22:08 — 5 Jul, 22:08
Sources
Showing 1 of 1 sources
